| Patient | Judy Garland |
|---|---|
| Date of birth | 1993-06-10 |
| Identifiers | MRN HR-ML005-SYN; SSN (made up) 000-05-6127 |
| Document date | 2026-06-22 |
| Author | Margaret Ellsworth-Diaz, MD |
| Custodian | St. Posthumous Health Center |
Readable copy of the C-CDA narrative, generated with the XML. Coded entries are in the XML file beside this page.
Establishing primary care for long-term prescribed sleeping pills and stimulants that began in adolescence: a nonjudgmental assessment, a prescription drug monitoring program review, sleep, mood, anxiety and safety, nutrition, and contraception three months after childbirth [S]
This fictional modern episode addresses the presenting concerns below. [S]
Historical basis. These claims are historical evidence, not findings from a modern examination.
3 later historical claims are omitted because they describe events after the index age. See the teaching note.
Historical biography with true dates. These events are not part of the synthetic care timeline.
| Historical date | History | Evidence |
|---|---|---|
| by 1939 | Stimulant pills for appetite and energy and barbiturate sleeping pills given to her as a teenage studio performer, with dependence on prescribed medicines since | D (CLM-0003, CLM-0005) |
| 1949 | Hospital and sanitarium stays in her twenties, publicly described as treatment for exhaustion | D (CLM-0007) |
| 1950 | Suicide attempts reported publicly, including one in 1950; recorded without detail | D (CLM-0006) |
| March 1955 | Birth of her third child three months before the index visit | D (CLM-0010) |
No family medical history is documented in the logged sources. Family history of real relatives is recorded only from documented or retrospective sources and is never synthesized.
| Allergy | Reaction | Status | Evidence |
|---|---|---|---|
| No known allergy | active | S |
| Medication | Frequency | Route | Dates | Status | Evidence |
|---|---|---|---|---|---|
| Secobarbital 100 mg oral capsule, two capsules (200 mg) at bedtime; prescribed elsewhere for years; continued by this clinic at the verified dose, seven days at a time, until a supervised withdrawal is planned with addiction medicine | Two capsules at bedtime; no extra doses | Oral route | 2026-06-22 to 2026-07-06 | completed | S |
| Dextroamphetamine 10 mg oral tablet, one tablet each morning; no extra doses; prescribed elsewhere for weight and energy | One tablet each morning | Oral route | 2026-06-22 to 2026-07-20 | completed | S |
| Sertraline 25 mg oral tablet, one tablet daily | One tablet daily | Oral route | 2026-06-22 to 2026-06-29 | completed | S |
| Medroxyprogesterone acetate 150 mg/mL injection, 150 mg into the muscle every 13 weeks | 150 mg intramuscularly every 13 weeks | Intramuscular route | 2026-06-22 | active | S |
Positive for the concerns in the history of present illness. Alert, warm and quick, anxious at first and then candid; speech normal in rate; no signs of intoxication or withdrawal. Mood low and worried; PHQ-9 14 with item 9 scored 0, GAD-7 13; Mood Disorder Questionnaire negative; no thoughts of suicide or self-harm now. No other systems reported as affected in this synthetic episode. [S]
Alert and engaged. Independent in all activities; groggy in the mornings and tired in the afternoons; works long days. [S]
Vital signs recorded on 2026-06-22; see the Vital Signs section. Mental status: Alert, warm and quick, anxious at first and then candid; speech normal in rate; no signs of intoxication or withdrawal; Mood low and worried; PHQ-9 14 with item 9 scored 0, GAD-7 13; Mood Disorder Questionnaire negative; no thoughts of suicide or self-harm now. The physical examination is limited to the findings relevant to this synthetic episode. [S]
Structured safety assessment: current ideation absent, intent absent, plan absent, access to means reviewed: yes. Outpatient care with close follow-up. Risk factors reviewed without detail: past suicide attempts reported in earlier years, a sedative use disorder, depression, the months after childbirth, and the low mood that can follow stopping a stimulant. Barbiturates are dangerous in overdose, so means safety is part of the plan: she agreed to take the unused capsules from earlier prescriptions to a pharmacy take-back at the next visit, to keep the current supply in a locked box, and to receive no more than seven days at a time. No alcohol with the barbiturate. A written safety plan was made with her, and the 988 Suicide & Crisis Lifeline (call or text 988) was saved in her phone. Safety is reviewed at every visit. [S]
| Date | Measure | Value | Unit | Provenance |
|---|---|---|---|---|
| 2026-06-22 | Body height | 151 | cm | S |
| 2026-06-22 | Body weight | 46.5 | kg | S |
| 2026-06-22 | Body mass index (BMI) [Ratio] | 20.4 | kg/m2 | S |
| 2026-06-22 | Systolic blood pressure | 128 | mm[Hg] | S |
| 2026-06-22 | Diastolic blood pressure | 84 | mm[Hg] | S |
| 2026-06-22 | Heart rate | 98 | /min | S |
| 2026-06-22 | Respiratory rate | 16 | /min | S |
| 2026-06-22 | Body temperature | 36.8 | Cel | S |
| 2026-06-22 | Oxygen saturation in Arterial blood by Pulse oximetry | 99 | % | S |
| Date | Measure | Value | Unit | Reference range | Flag | Provenance |
|---|---|---|---|---|---|---|
| 2026-06-22 | Hemoglobin [Mass/volume] in Blood | 12.3 | g/dL | 12-15.5 g/dL | Normal | S |
| 2026-06-22 | MCV [Entitic mean volume] in Red Blood Cells by Automated count | 86 | fL | 80-100 fL | Normal | S |
| 2026-06-22 | Platelets [#/volume] in Blood by Automated count | 284 | 10*3/uL | 150-400 10*3/uL | Normal | S |
| 2026-06-22 | Ferritin [Mass/volume] in Serum or Plasma | 24 | ng/mL | 15-150 ng/mL | Normal | S |
| 2026-06-22 | Sodium [Moles/volume] in Serum or Plasma | 139 | mmol/L | 135-145 mmol/L | Normal | S |
| 2026-06-22 | Potassium [Moles/volume] in Serum or Plasma | 4.1 | mmol/L | 3.5-5.1 mmol/L | Normal | S |
| 2026-06-22 | Creatinine [Mass/volume] in Serum or Plasma | 0.66 | mg/dL | 0.59-1.04 mg/dL | Normal | S |
| 2026-06-22 | Glomerular filtration rate [Volume Rate/Area] in Serum, Plasma or Blood by Creatinine-based formula (CKD-EPI 2021)/1.73 sq M | 119 | mL/min/{1.73_m2} | >=60 mL/min/1.73 m² | Normal | S |
| 2026-06-22 | Glucose [Mass/volume] in Serum or Plasma | 82 | mg/dL | 70-99 mg/dL | Normal | S |
| 2026-06-22 | Aspartate aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 21 | U/L | 10-35 U/L | Normal | S |
| 2026-06-22 | Alanine aminotransferase [Enzymatic activity/volume] in Serum or Plasma | 18 | U/L | 7-35 U/L | Normal | S |
| 2026-06-22 | Gamma glutamyl transferase [Enzymatic activity/volume] in Serum or Plasma | 24 | U/L | 5-40 U/L | Normal | S |
| 2026-06-22 | Thyrotropin [Units/volume] in Serum or Plasma | 1.9 | m[IU]/L | 0.4-4.5 mIU/L | Normal | S |
| 2026-06-22 | Total score [DAST-10] | 6 | {score} | S | ||
| 2026-06-22 | Total score [AUDIT-C] | 2 | {score} | S | ||
| 2026-06-22 | Patient Health Questionnaire 9 item (PHQ-9) total score [Reported] | 14 | {score} | S | ||
| 2026-06-22 | Generalized anxiety disorder 7 item (GAD-7) total score [Reported.PHQ] | 13 | {score} | S |
| Problem | Clinical status | Verification | Code | Provenance |
|---|---|---|---|---|
| Sedative, hypnotic, or anxiolytic use disorder (barbiturate), moderate, with physiological dependence; began with sleeping pills given in adolescence; synthetic modern episode linked to her documented lifelong dependence on prescribed sleeping pills | active | confirmed | F13.20 | S — Synthetic modern coding. Tolerance and withdrawal are not counted toward the diagnosis for a medicine taken under medical supervision; five other criteria are met. Person-first language; not a claim about her real diagnosis. |
| Stimulant use disorder (prescribed amphetamine), mild; began with stimulants given in adolescence for weight and energy; synthetic modern episode linked to her documented pep pills | active | confirmed | F15.10 | S — Synthetic modern coding; DSM-5-TR mild stimulant use disorder maps to F15.10. Tolerance and withdrawal are not counted for a supervised prescription. |
| Chronic insomnia disorder, long-standing, with sleep tied to sleeping pills since adolescence | active | confirmed | G47.00 | S — Synthetic modern diagnosis anchored to the documented sleeping pills. |
| Contraception three months after childbirth while starting an enzyme-inducing drug: injectable progestin chosen because barbiturates, including any used for the withdrawal, weaken contraceptive pills, patches, rings and implants | active | confirmed | Z30.013 | S — Synthetic contraception need; the birth is documented. |
| Major depressive disorder, single episode, moderate, with anxious distress; Mood Disorder Questionnaire negative and no history of mania or hypomania | active | confirmed | F32.1 | S — Synthetic modern diagnosis; not a claim about her real mood. The roster's bipolar disorder lead is not supported by the sources read and is not used. |